Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia

Dylan A. Mordaunt; Kim Dalziel; Ilias Goranitis; Zornitza Stark

doi:10.1038/s41431-023-01417-6

Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia

Dylan A. Mordaunt, Kim Dalziel, Ilias Goranitis, Zornitza Stark

Research output: Contribution to journal › Comment/debate

27 Citations (Scopus)

48 Downloads (Pure)

Abstract

Lack of reimbursement for genomic testing in rare diseases is recognized as one of the principal barriers to wider implementation within healthcare systems [1]. Multiple studies have provided evidence for diagnostic and clinical utility and for the cost-effectiveness of genomic testing in rare diseases, leading to testing being funded across a range of public and private healthcare systems worldwide [2].

Original language	English
Pages (from-to)	977-979
Number of pages	3
Journal	European Journal of Human Genetics
Volume	31
Issue number	9
Early online date	3 Jul 2023
DOIs	https://doi.org/10.1038/s41431-023-01417-6
Publication status	Published - Sept 2023
Externally published	Yes

Keywords

economics
health care
health care economics
health policy

Access to Document

10.1038/s41431-023-01417-6Licence: CC BY

Final published versionFinal published version, 497 KBLicence: CC BY

Cite this

@article{b1225fbc7a4940afa84acbd498de27d5,

title = "Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia",

abstract = "Lack of reimbursement for genomic testing in rare diseases is recognized as one of the principal barriers to wider implementation within healthcare systems [1]. Multiple studies have provided evidence for diagnostic and clinical utility and for the cost-effectiveness of genomic testing in rare diseases, leading to testing being funded across a range of public and private healthcare systems worldwide [2].",

keywords = "economics, health care, health care economics, health policy",

author = "Mordaunt, {Dylan A.} and Kim Dalziel and Ilias Goranitis and Zornitza Stark",

year = "2023",

month = sep,

doi = "10.1038/s41431-023-01417-6",

language = "English",

volume = "31",

pages = "977--979",

journal = "European Journal of Human Genetics",

issn = "1018-4813",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia

AU - Mordaunt, Dylan A.

AU - Dalziel, Kim

AU - Goranitis, Ilias

AU - Stark, Zornitza

PY - 2023/9

Y1 - 2023/9

N2 - Lack of reimbursement for genomic testing in rare diseases is recognized as one of the principal barriers to wider implementation within healthcare systems [1]. Multiple studies have provided evidence for diagnostic and clinical utility and for the cost-effectiveness of genomic testing in rare diseases, leading to testing being funded across a range of public and private healthcare systems worldwide [2].

AB - Lack of reimbursement for genomic testing in rare diseases is recognized as one of the principal barriers to wider implementation within healthcare systems [1]. Multiple studies have provided evidence for diagnostic and clinical utility and for the cost-effectiveness of genomic testing in rare diseases, leading to testing being funded across a range of public and private healthcare systems worldwide [2].

KW - economics

KW - health care

KW - health care economics

KW - health policy

UR - http://www.scopus.com/inward/record.url?scp=85164182093&partnerID=8YFLogxK

U2 - 10.1038/s41431-023-01417-6

DO - 10.1038/s41431-023-01417-6

M3 - Comment/debate

C2 - 37400487

AN - SCOPUS:85164182093

SN - 1018-4813

VL - 31

SP - 977

EP - 979

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

IS - 9

ER -

Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this